Search Results

You are looking at 111 - 111 of 111 items for :

  • "aromatase inhibitor" x
Clear All
Full access

used to assess discontinuation rates, adjusting for censoring. Results : Data were collected on 401 patients. In first-line therapy for mBC, 52.4% of patients received a palbociclib-based regimen. Other common first-line regimens included aromatase